IDEXX Laboratories (NASDAQ:IDXX) 주식

IDEXX Laboratories

Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets close to 35% of its revenue from outside the United States.

Chatbot,Conversation,Ai,Artificial,Intelligence,Technology,Online,Customer,Service.digital,Chatbot,

News

Commodities

Markets

AXON

CPNG

IDXX

ISRG

MELI

PCAR

SPOT

케이티 허버티(Katy Huberty)는 모건 스탠리의 글로벌 리서치 책임자로, 인공지능(AI) 도입으로 인해 상당한 이점을 얻을 가능성이 있는 20개의 주식을 주목했다. 무슨 일이 있었나: 허버티는 현재 AI 도입을 위한 &#34;전환점&#34;에 있다고 언급했다. 그녀는 AI를 활용하여 수익을 증대시키는 기업들이 상당한 혜택을 누릴 준비가 되어 있다고 강조했다.

모건 스탠리, 인공지능 채택이 임계치에 도달함에 따라 상위 20개 AI 기반 주식 공개

Healthcare,,Opioid,Epidemic,And,Drug,Abuse,Concept,With,The,Map

Analyst Color

Biotech

Large Cap

Health Care

Analyst Ratings

Trading Ideas

General

ABBV

ELAN

GILD

PRGO

REGN

TEVA

VTRS

JP모건에 따르면 미국 대형 바이오제약주는 2년 연속 전체 시장 대비 저조한 실적을 기록했으며, 2025년에 대한 투자자들의 전망은 혼조세를 보이고 있다. 강력한 펀더멘털과 신약 파이프라인의 발전에도 불구하고 정치적 불확실성과 섹터 순환과 같은 요인으로 인해 S&amp;P 500 대비 바이오제약 섹터의 성과가 저조했다. 

일라이 릴리, 머크 등 대형 바이오제약사 2025년 전망: JP모건

IDEXX Laboratories Inc

Daniel M Junius, Director at IDEXX Laboratories (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IDXX#NASDAQ">IDXX</a>), reported a large exercise of company stock options on May 14, according to a new SEC filing.
What Happened: Junius, Director at IDEXX Laboratories, exercised stock options for 2,683 shares of IDXX stock. This information was disclosed in a Form 4 filing with the <a href="https://www.sec.gov/Archives/edgar/data/0000874716/000087471625000090//Archives/edgar/data/874716/000087471625000090/0000874716-25-000090-index.htm">U.S. Securities and Exchange Commission</a> on Wednesday. The exercise price of the options was $263.81 per share.
Currently, IDEXX Laboratories shares are trading down 0.02%, priced at $509.31 during Thursday's morning. This values Junius's 2,683 shares at $658,691.
<h3>Delving into IDEXX Laboratories's Background</h3>
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets close to 35% of its revenue from outside the United States.
<h3>Breaking Down IDEXX Laboratories's Financial Performance</h3>
Revenue Growth: IDEXX Laboratories displayed positive results in 3 months. As of 31 March, 2025, the company achieved a solid revenue growth rate of approximately 3.56%. This indicates a notable increase in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Health Care sector.
Insights into Profitability:
<ul>
<li>
Gross Margin: The company maintains a high gross margin of 62.44%, indicating strong cost management and profitability compared to its peers.
</li>
<li>
Earnings per Share (EPS): The company excels with an EPS that surpasses the industry average. With a current EPS of 2.98, IDEXX Laboratories showcases strong earnings per share.
</li>
</ul>
Debt Management: With a high debt-to-equity ratio of 0.73, IDEXX Laboratories faces challenges in effectively managing its debt levels, indicating potential financial strain.
Valuation Analysis:
<ul>
<li>
Price to Earnings (P/E) Ratio: IDEXX Laboratories's P/E ratio of 47.08 is below the industry average, suggesting the stock may be undervalued.
</li>
<li>
Price to Sales (P/S) Ratio: A higher-than-average P/S ratio of 10.72 suggests overvaluation in the eyes of investors, considering sales performance.
</li>
<li>
EV/EBITDA Analysis (Enterprise Value to its Earnings Before Interest, Taxes, Depreciation &amp; Amortization): Boasting an EV/EBITDA ratio of 32.47, IDEXX Laboratories demonstrates a robust market valuation, outperforming industry benchmarks.
</li>
</ul>
Market Capitalization Perspectives: The company's market capitalization falls below industry averages, signaling a relatively smaller size compared to peers. This positioning may be influenced by factors such as perceived growth potential or operational scale.
<a href="https://www.schwab.com/brokerage?aff=XEC">Now trade stocks online commission free with Charles Schwab, a trusted and complete investment firm.</a>
<h3>Unmasking the Significance of Insider Transactions</h3>
In the complex landscape of investment decisions, investors should approach insider transactions as part of a comprehensive analysis, considering various elements.
Exploring the legal landscape, an "insider" is defined as any officer, director, or beneficial owner holding more than ten percent of a company's equity securities, as stipulated by Section 12 of the Securities Exchange Act of 1934. This encompasses executives in the c-suite and major hedge funds. These insiders are required to report their transactions through a Form 4 filing, which must be submitted within two business days of the transaction.
Highlighted by a company insider's new purchase, there's a positive anticipation for the stock to rise.
But, insider sells may not necessarily indicate a bearish view and can be motivated by various factors.
<h3>Understanding Crucial Transaction Codes</h3>
Taking a closer look at transactions, <a href="https://www.benzinga.com/money/investing-tools">investors</a> often prioritize those unfolding in the open market, meticulously cataloged in Table I of the Form 4 filing. A P in Box 3 denotes a purchase, while S signifies a sale. Transaction code C denotes the conversion of an option, and transaction code A signifies a grant, award, or other acquisition of securities from the company.
<a href="https://www.benzinga.com/sec/insider-trades/search/index?company_cik=0000874716">Check Out The Full List Of IDEXX Laboratories's Insider Trades.</a>
Insider Buying Alert: Profit from C-Suite Moves
Benzinga Edge reveals every insider trade in real-time. Don't miss the next big stock move driven by insider confidence. Unlock this ultimate sentiment indicator now. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22in8&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here for access</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Insider Trades

Daniel M Junius At IDEXX Laboratories Capitalizes: Options Exercised, Resulting In $658K

Sophie V Vandebroek, Board Member at IDEXX Laboratories (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IDXX#NASDAQ">IDXX</a>), reported a large exercise of company stock options on May 13, according to a new SEC filing.
What Happened: A Form 4 filing with the <a href="https://www.sec.gov/Archives/edgar/data/0000874716/000087471625000088//Archives/edgar/data/874716/000087471625000088/0000874716-25-000088-index.htm">U.S. Securities and Exchange Commission</a> on Tuesday revealed that Vandebroek, Board Member at IDEXX Laboratories in the Health Care sector, exercised stock options for 1,279 shares of IDXX stock. The exercise price of the options was $283.59 per share.
IDEXX Laboratories shares are trading down 0.0% at $509.13 at the time of this writing on Wednesday morning. Since the current price is $509.13, this makes Vandebroek's 1,279 shares worth $288,465.
<h3>All You Need to Know About IDEXX Laboratories</h3>
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets close to 35% of its revenue from outside the United States.
<h3>Financial Insights: IDEXX Laboratories</h3>
Revenue Growth: Over the 3 months period, IDEXX Laboratories showcased positive performance, achieving a revenue growth rate of 3.56% as of 31 March, 2025. This reflects a substantial increase in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.
Insights into Profitability:
<ul>
<li>
Gross Margin: The company sets a benchmark with a high gross margin of 62.44%, reflecting superior cost management and profitability compared to its peers.
</li>
<li>
Earnings per Share (EPS): IDEXX Laboratories's EPS is notably higher than the industry average. The company achieved a positive bottom-line trend with a current EPS of 2.98.
</li>
</ul>
Debt Management: IDEXX Laboratories's debt-to-equity ratio is notably higher than the industry average. With a ratio of 0.73, the company relies more heavily on borrowed funds, indicating a higher level of financial risk.
Assessing Valuation Metrics:
<ul>
<li>
Price to Earnings (P/E) Ratio: The current P/E ratio of 47.05 is below industry norms, indicating potential undervaluation and presenting an investment opportunity.
</li>
<li>
Price to Sales (P/S) Ratio: With a higher-than-average P/S ratio of 10.71, IDEXX Laboratories's stock is perceived as being overvalued in the market, particularly in relation to sales performance.
</li>
<li>
EV/EBITDA Analysis (Enterprise Value to its Earnings Before Interest, Taxes, Depreciation &amp; Amortization): IDEXX Laboratories's EV/EBITDA ratio of 32.45 exceeds industry averages, indicating a premium valuation in the market
</li>
</ul>
Market Capitalization Analysis: Below industry benchmarks, the company's market capitalization reflects a smaller scale relative to peers. This could be attributed to factors such as growth expectations or operational capacity.
<a href="https://www.schwab.com/brokerage?aff=XEC">Now trade stocks online commission free with Charles Schwab, a trusted and complete investment firm.</a>
<h3>Uncovering the Importance of Insider Activity</h3>
Insider transactions shouldn't be used primarily to make an investing decision, however an insider transaction can be an important factor in the investing decision. 
Considering the legal perspective, an "insider" is defined as any officer, director, or beneficial owner holding more than ten percent of a company's equity securities, according to Section 12 of the Securities Exchange Act of 1934. This includes executives in the c-suite and major hedge funds. These insiders are mandated to disclose their transactions through a Form 4 filing, to be submitted within two business days of the transaction.
Pointing towards optimism, a company insider's new purchase signals their positive anticipation for the stock to rise.
Nevertheless, insider sells may not necessarily indicate a bearish view and can be influenced by various factors.
<h3>A Deep Dive into Insider Transaction Codes</h3>
For <a href="https://www.benzinga.com/money/investing-tools">investors</a>, a primary focus lies on transactions occurring in the open market, as indicated in Table I of the Form 4 filing. A P in Box 3 denotes a purchase, while S signifies a sale. Transaction code C signals the conversion of an option, and transaction code A denotes a grant, award, or other acquisition of securities from the company.
<a href="https://www.benzinga.com/sec/insider-trades/search/index?company_cik=0000874716">Check Out The Full List Of IDEXX Laboratories's Insider Trades.</a>
Insider Buying Alert: Profit from C-Suite Moves
Benzinga Edge reveals every insider trade in real-time. Don't miss the next big stock move driven by insider confidence. Unlock this ultimate sentiment indicator now. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22in8&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here for access</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Insider Decision: Sophie V Vandebroek Exercises Options At IDEXX Laboratories For $288K

IDEXX Laboratories's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IDXX#NYSE">IDXX</a>) short percent of float has risen 5.92% since its last report. The company recently reported that it has 3.00 million shares sold short, which is 4.83% of all regular shares that are available for trading. Based on its trading volume, it would take traders 2.44 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">List of the most shorted stocks</a>
<h3>IDEXX Laboratories Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1746802832_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for IDEXX Laboratories has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing IDEXX Laboratories's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>, IDEXX Laboratories's peer group average for short interest as a percentage of float is 4.13%, which means the company has more short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

Is the Market Bullish or Bearish on IDEXX Laboratories?

Morgan Stanley analyst Erin Wright maintains IDEXX Laboratories (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IDXX#NASDAQ">IDXX</a>) with a Overweight and raises the price target from $548 to $558.

Price Target

Morgan Stanley Maintains Overweight on IDEXX Laboratories, Raises Price Target to $558

WIIM

IDEXX Laboratories shares are trading higher after the company reported better-than-expected Q1 financial results and raised its FY25 EPS guidance above estimates. Also, the company raised its FY25 sales guidance with its midpoint above estimates.

IDEXX Laboratories (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IDXX#NASDAQ">IDXX</a>) raises FY2025 GAAP EPS guidance from $11.74-$12.24 to $11.93-$12.43 vs $11.91 analyst estimate. Raises FY2025 sales outlook from $4.05 billion-$4.17 billion to $4.09 billion-$4.21 billion vs $4.12 billion estimate.

Guidance

IDEXX Laboratories Raises FY2025 GAAP EPS Guidance from $11.74-$12.24 to $11.93-$12.43 vs $11.91 Est; Raises FY2025 Sales Guidance from $4.05B-$4.17B to $4.09B-$4.21B vs $4.12B Est

Earnings

Earnings Beats

IDEXX Laboratories Q1 Adj. EPS $2.91 Beats $2.85 Estimate, Sales $998.43M Beat $998.15M Estimate

AAMI

AAPL

ABNB

ACCO

ADPT

AGCO

AGIO

ALHC

ALKS

ALNY

ALSN

AMGN

AMWL

AMZN

APLE

APTV

ARDX

ARVN

ASND

ASPS

ASUR

ATEC

ATEN

AXTI

BBAI

BIIB

BJRI

BLDR

BMRN

BOOM

BPMC

BRFH

CABO

CARR

CART

CERS

CMLS

COHN

COHU

COLM

COMM

COOK

CRAI

CTRE

CUBE

CWST

DBRG

DINO

DSGR

DUOL

DXCM

ECVT

ELME

Earnings Scheduled For May 1, 2025

IDEXX Laboratories (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IDXX#NASDAQ">IDXX</a>) has outperformed the market over the past 10 years by 11.03% on an annualized basis producing an average annual return of 21.28%. Currently, IDEXX Laboratories has a market capitalization of $35.41 billion. 
Buying $100 In IDXX: If an investor had bought $100 of IDXX stock 10 years ago, it would be worth $669.58 today based on a price of $436.97 for IDXX at the time of writing.
<h3>IDEXX Laboratories's Performance Over Last 10 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1745970316_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Here's How Much $100 Invested In IDEXX Laboratories 10 Years Ago Would Be Worth Today

Looking into the current session, IDEXX Laboratories Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IDXX#NASDAQ">IDXX</a>) shares are trading at $409.49, after a 0.70% increase. Moreover, over the past month, the stock increased by 0.04%, but in the past year, decreased by 15.47%. Shareholders might be interested in knowing whether the stock is undervalued, even if the company is performing up to par in the current session. 

<img src="https://www.benzinga.com/files/images/story/2025/1745344821_0_0.png" alt="Past Year Chart" />

<h3>How Does IDEXX Laboratories P/E Compare to Other Companies?</h3>
The P/E ratio measures the current share price to the company's EPS. It is used by long-term investors to analyze the company's current performance against it's past earnings, historical data and aggregate market data for the industry or the indices, such as S&amp;P 500. A higher P/E indicates that investors expect the company to perform better in the future, and the stock is probably overvalued, but not necessarily. It also could indicate that investors are willing to pay a higher share price currently, because they expect the company to perform better in the upcoming quarters. This leads investors to also remain optimistic about rising dividends in the future. 
Compared to the aggregate P/E ratio of the 78.64 in the Health Care Equipment &amp; Supplies industry, IDEXX Laboratories Inc. has a lower P/E ratio of 38.11. Shareholders might be inclined to think that the stock might perform worse than it's industry peers. It's also possible that the stock is undervalued. 

<img src="https://www.benzinga.com/files/images/story/2025/1745344821_1.png" alt="Guage" />

In summary, while the price-to-earnings ratio is a valuable tool for investors to evaluate a company's market performance, it should be used with caution. A low P/E ratio can be an indication of undervaluation, but it can also suggest weak growth prospects or financial instability. Moreover, the P/E ratio is just one of many metrics that investors should consider when making investment decisions, and it should be evaluated alongside other financial ratios, industry trends, and qualitative factors. By taking a comprehensive approach to analyzing a company's financial health, investors can make well-informed decisions that are more likely to lead to successful outcomes.

Intraday Update

A Look Into IDEXX Laboratories Inc's Price Over Earnings

Stifel analyst Jonathan Block maintains IDEXX Laboratories (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IDXX#NASDAQ">IDXX</a>) with a Hold and lowers the price target from $450 to $420.

Stifel Maintains Hold on IDEXX Laboratories, Lowers Price Target to $420

IDEXX Laboratories's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IDXX#NYSE">IDXX</a>) short percent of float has risen 10.37% since its last report. The company recently reported that it has 3.02 million shares sold short, which is 4.79% of all regular shares that are available for trading. Based on its trading volume, it would take traders 3.8 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">List of the most shorted stocks</a>
<h3>IDEXX Laboratories Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1743790503_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for IDEXX Laboratories has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing IDEXX Laboratories's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>, IDEXX Laboratories's peer group average for short interest as a percentage of float is 4.39%, which means the company has more short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

How Is The Market Feeling About IDEXX Laboratories?

Legal

U.S. Judge Dismisses Most Of Consumer Lawsuit Against Idexx Laboratories Over Veterinary Service Prices

A substantial insider activity was disclosed on February 12, as Erickson, Executive Vice President at IDEXX Laboratories (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IDXX#NASDAQ">IDXX</a>), reported the exercise of a large sell of company stock options.
What Happened: Disclosed in a Form 4 filing on Wednesday with the <a href="https://www.sec.gov/Archives/edgar/data/0000874716/000087471625000008//Archives/edgar/data/874716/000087471625000008/0000874716-25-000008-index.htm">U.S. Securities and Exchange Commission</a>, Erickson, Executive Vice President at IDEXX Laboratories, executed a strategic derivative sale. This involved exercising stock options for 1,544 shares of IDXX, resulting in a transaction value of $597,944.
As of Thursday morning, IDEXX Laboratories shares are down by 0.49%, with a current price of $455.12. This implies that Erickson's 1,544 shares have a value of $597,944.
<h3>Discovering IDEXX Laboratories: A Closer Look</h3>
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets close to 35% of its revenue from outside the United States.
<h3>IDEXX Laboratories: Delving into Financials</h3>
Decline in Revenue: Over the 3 months period, IDEXX Laboratories faced challenges, resulting in a decline of approximately -2.18% in revenue growth as of 31 December, 2024. This signifies a reduction in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Health Care sector.
Evaluating Earnings Performance:
<ul>
<li>
Gross Margin: The company excels with a remarkable gross margin of 59.8%, indicating superior cost efficiency and profitability compared to its industry peers.
</li>
<li>
Earnings per Share (EPS): The company excels with an EPS that surpasses the industry average. With a current EPS of 2.64, IDEXX Laboratories showcases strong earnings per share.
</li>
</ul>
Debt Management: IDEXX Laboratories's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.54.
In-Depth Valuation Examination:
<ul>
<li>
Price to Earnings (P/E) Ratio: The P/E ratio of 42.86 is lower than the industry average, implying a discounted valuation for IDEXX Laboratories's stock.
</li>
<li>
Price to Sales (P/S) Ratio: With a relatively high Price to Sales ratio of 9.77 as compared to the industry average, the stock might be considered overvalued based on sales performance.
</li>
<li>
EV/EBITDA Analysis (Enterprise Value to its Earnings Before Interest, Taxes, Depreciation &amp; Amortization): The company's EV/EBITDA ratio of 33.7 trails industry averages, indicating a potential disparity in market valuation that could be advantageous for investors.
</li>
</ul>
Market Capitalization Analysis: Reflecting a smaller scale, the company's market capitalization is positioned below industry averages. This could be attributed to factors such as growth expectations or operational capacity.
<a href="https://www.schwab.com/brokerage?aff=XEC">Now trade stocks online commission free with Charles Schwab, a trusted and complete investment firm.</a>
<h3>Why Insider Transactions Are Key in Investment Decisions</h3>
Insider transactions, although significant, should be considered within the larger context of market analysis and trends.
Within the legal framework, an "insider" is defined as any officer, director, or beneficial owner holding more than ten percent of a company's equity securities as per Section 12 of the Securities Exchange Act of 1934. This includes executives in the c-suite and major hedge funds. These insiders are mandated to disclose their transactions through a Form 4 filing, to be submitted within two business days of the transaction.
The initiation of a new purchase by a company insider serves as a strong indication that they expect the stock to rise.
However, insider sells may not always signal a bearish view and can be influenced by various factors.
<h3>Transaction Codes To Focus On</h3>
When dissecting transactions, the focal point for <a href="https://www.benzinga.com/money/investing-tools">investors</a> is often those occurring in the open market, meticulously detailed in Table I of the Form 4 filing. A P in Box 3 denotes a purchase, while S signifies a sale. Transaction code C indicates the conversion of an option, and transaction code A denotes a grant, award, or other acquisition of securities from the company.
<a href="https://www.benzinga.com/sec/insider-trades/search/index?company_cik=0000874716">Check Out The Full List Of IDEXX Laboratories's Insider Trades.</a>
Insider Buying Alert: Profit from C-Suite Moves
Benzinga Edge reveals every insider trade in real-time. Don't miss the next big stock move driven by insider confidence. Unlock this ultimate sentiment indicator now. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22in8&amp;utm_source=benzinga-insights">Click here for access</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Options Movement At IDEXX Laboratories: Michael G Erickson Exercises Worth $597K

In a new SEC filing on February 11, it was revealed that Fennell, Executive Vice President at IDEXX Laboratories (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IDXX#NASDAQ">IDXX</a>), executed a significant exercise of company stock options.
What Happened: In an insider options sale disclosed in a Form 4 filing on Tuesday with the <a href="https://www.sec.gov/Archives/edgar/data/0000874716/000087471625000006//Archives/edgar/data/874716/000087471625000006/0000874716-25-000006-index.htm">U.S. Securities and Exchange Commission</a>, Fennell, Executive Vice President at IDEXX Laboratories, exercised stock options for 11,242 shares of IDXX. The transaction value amounted to $4,280,728.
The Wednesday morning market activity shows IDEXX Laboratories shares down by 0.74%, trading at $460.32. This implies a total value of $4,280,728 for Fennell's 11,242 shares.
<h3>Delving into IDEXX Laboratories's Background</h3>
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets close to 35% of its revenue from outside the United States.
<h3>A Deep Dive into IDEXX Laboratories's Financials</h3>
Negative Revenue Trend: Examining IDEXX Laboratories's financials over 3 months reveals challenges. As of 31 December, 2024, the company experienced a decline of approximately -2.18% in revenue growth, reflecting a decrease in top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Health Care sector.
Profitability Metrics:
<ul>
<li>
Gross Margin: The company excels with a remarkable gross margin of 59.8%, indicating superior cost efficiency and profitability compared to its industry peers.
</li>
<li>
Earnings per Share (EPS): IDEXX Laboratories's EPS is a standout, portraying a positive bottom-line trend that exceeds the industry average with a current EPS of 2.64.
</li>
</ul>
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 0.54.
Financial Valuation:
<ul>
<li>
Price to Earnings (P/E) Ratio: The P/E ratio of 43.46 is lower than the industry average, implying a discounted valuation for IDEXX Laboratories's stock.
</li>
<li>
Price to Sales (P/S) Ratio: With a higher-than-average P/S ratio of 9.9, IDEXX Laboratories's stock is perceived as being overvalued in the market, particularly in relation to sales performance.
</li>
<li>
EV/EBITDA Analysis (Enterprise Value to its Earnings Before Interest, Taxes, Depreciation &amp; Amortization): With a below-average EV/EBITDA ratio of 34.17, IDEXX Laboratories presents an opportunity for value investors. This lower valuation may attract investors seeking undervalued opportunities.
</li>
</ul>
Market Capitalization Analysis: The company exhibits a lower market capitalization profile, positioning itself below industry averages. This suggests a smaller scale relative to peers.
<a href="https://www.schwab.com/brokerage?aff=XEC">Now trade stocks online commission free with Charles Schwab, a trusted and complete investment firm.</a>
<h3>The Relevance of Insider Transactions</h3>
While insider transactions should not be the sole basis for making investment decisions, they can play a significant role in an investor's decision-making process.
In the context of legal matters, the term "insider" refers to any officer, director, or beneficial owner holding more than ten percent of a company's equity securities, as outlined by Section 12 of the Securities Exchange Act of 1934. This includes executives in the c-suite and significant hedge funds. Such insiders are obligated to report their transactions through a Form 4 filing, which must be completed within two business days of the transaction.
Pointing towards optimism, a company insider's new purchase signals their positive anticipation for the stock to rise.
Despite insider sells not always signaling a bearish sentiment, they can be driven by various factors.
<h3>Exploring Key Transaction Codes</h3>
Examining transactions, <a href="https://www.benzinga.com/money/investing-tools">investors</a> often concentrate on those unfolding in the open market, meticulously detailed in Table I of the Form 4 filing. A P in Box 3 denotes a purchase, while S signifies a sale. Transaction code C indicates the conversion of an option, and transaction code A denotes a grant, award, or other acquisition of securities from the company.
<a href="https://www.benzinga.com/sec/insider-trades/search/index?company_cik=0000874716">Check Out The Full List Of IDEXX Laboratories's Insider Trades.</a>
Insider Buying Alert: Profit from C-Suite Moves
Benzinga Edge reveals every insider trade in real-time. Don't miss the next big stock move driven by insider confidence. Unlock this ultimate sentiment indicator now. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22in8&amp;utm_source=benzinga-insights">Click here for access</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Insider Decision: George Fennell Exercises Options At IDEXX Laboratories For $4.28M

A substantial insider sell was reported on February 10, by M. Anne Szostak, Director at IDEXX Laboratories (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IDXX#NASDAQ">IDXX</a>), based on the recent SEC filing.
What Happened: Szostak's recent move involves selling 3,000 shares of IDEXX Laboratories. This information is documented in a Form 4 filing with the <a href="https://www.sec.gov/Archives/edgar/data/0000874716/000087471625000004//Archives/edgar/data/874716/000087471625000004/0000874716-25-000004-index.htm">U.S. Securities and Exchange Commission</a> on Monday. The total value is $1,397,835.
Tracking the Tuesday's morning session, IDEXX Laboratories shares are trading at $463.0, showing a down of 0.41%.
<h3>About IDEXX Laboratories</h3>
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets close to 35% of its revenue from outside the United States.
<h3>IDEXX Laboratories: A Financial Overview</h3>
Revenue Challenges: IDEXX Laboratories's revenue growth over 3 months faced difficulties. As of 31 December, 2024, the company experienced a decline of approximately -2.18%. This indicates a decrease in top-line earnings. When compared to others in the Health Care sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Profitability Metrics: Unlocking Value
<ul>
<li>
Gross Margin: The company sets a benchmark with a high gross margin of 59.8%, reflecting superior cost management and profitability compared to its peers.
</li>
<li>
Earnings per Share (EPS): IDEXX Laboratories's EPS outshines the industry average, indicating a strong bottom-line trend with a current EPS of 2.64.
</li>
</ul>
Debt Management: IDEXX Laboratories's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.54.
Navigating Market Valuation:
<ul>
<li>
Price to Earnings (P/E) Ratio: The current P/E ratio of 43.57 is below industry norms, indicating potential undervaluation and presenting an investment opportunity.
</li>
<li>
Price to Sales (P/S) Ratio: The current P/S ratio of 9.93 is above industry norms, reflecting an elevated valuation for IDEXX Laboratories's stock and potential overvaluation based on sales performance.
</li>
<li>
EV/EBITDA Analysis (Enterprise Value to its Earnings Before Interest, Taxes, Depreciation &amp; Amortization): With an EV/EBITDA ratio lower than industry benchmarks at 34.25, IDEXX Laboratories presents an attractive value opportunity.
</li>
</ul>
Market Capitalization: Indicating a reduced size compared to industry averages, the company's market capitalization poses unique challenges.
<a href="https://www.schwab.com/brokerage?aff=XEC">Now trade stocks online commission free with Charles Schwab, a trusted and complete investment firm.</a>
<h3>Illuminating the Importance of Insider Transactions</h3>
Insider transactions shouldn't be used primarily to make an investing decision, however an insider transaction can be an important factor in the investing decision. 
Exploring the legal landscape, an "insider" is defined as any officer, director, or beneficial owner holding more than ten percent of a company's equity securities, as stipulated by Section 12 of the Securities Exchange Act of 1934. This encompasses executives in the c-suite and major hedge funds. These insiders are required to report their transactions through a Form 4 filing, which must be submitted within two business days of the transaction.
Highlighted by a company insider's new purchase, there's a positive anticipation for the stock to rise.
But, insider sells may not necessarily indicate a bearish view and can be motivated by various factors.
<h3>Deciphering Transaction Codes in Insider Filings</h3>
Digging into the details of stock transactions, <a href="https://www.benzinga.com/money/investing-tools">investors</a> frequently turn their attention to those taking place in the open market, as outlined in Table I of the Form 4 filing. A P in Box 3 indicates a purchase, while S signifies a sale. Transaction code C signals the conversion of an option, and transaction code A denotes a grant, award, or other acquisition of securities from the company.
<a href="https://www.benzinga.com/sec/insider-trades/search/index?company_cik=0000874716">Check Out The Full List Of IDEXX Laboratories's Insider Trades.</a>
Insider Buying Alert: Profit from C-Suite Moves
Benzinga Edge reveals every insider trade in real-time. Don't miss the next big stock move driven by insider confidence. Unlock this ultimate sentiment indicator now. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22in8&amp;utm_source=benzinga-insights">Click here for access</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

M. Anne Szostak Implements A Sell Strategy: Offloads $1.40M In IDEXX Laboratories Stock

Piper Sandler analyst David Westenberg maintains IDEXX Laboratories (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IDXX#NASDAQ">IDXX</a>) with a Neutral and raises the price target from $435 to $510.

Piper Sandler Maintains Neutral on IDEXX Laboratories, Raises Price Target to $510

Barclays analyst Balaji Prasad maintains IDEXX Laboratories (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IDXX#NASDAQ">IDXX</a>) with a Overweight and raises the price target from $481 to $520.

Barclays Maintains Overweight on IDEXX Laboratories, Raises Price Target to $520

B of A Securities analyst Michael Ryskin maintains IDEXX Laboratories (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IDXX#NASDAQ">IDXX</a>) with a Neutral and raises the price target from $475 to $535.

B of A Securities Maintains Neutral on IDEXX Laboratories, Raises Price Target to $535

<h3>Gainers</h3>
<ul>
<li>HCW Biologics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HCWB#NASDAQ">HCWB</a>) shares rose 251.2% to $0.98 during Monday's pre-market session. The market value of their outstanding shares is at $43.5 million. </li>
<li>GH Research (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GHRS#NASDAQ">GHRS</a>) shares rose 90.45% to $20.19. The company's market cap stands at $1.0 billion. </li>
<li>Invivyd (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IVVD#NASDAQ">IVVD</a>) stock moved upwards by 24.68% to $0.45. The company's market cap stands at $53.3 million. </li>
<li>Quince Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QNCX#NASDAQ">QNCX</a>) shares increased by 11.8% to $1.8. The company's market cap stands at $79.2 million. </li>
<li>Redhill Biopharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RDHL#NASDAQ">RDHL</a>) shares rose 10.67% to $6.54. The market value of their outstanding shares is at $8.3 million. </li>
<li>IDEXX Laboratories (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IDXX#NASDAQ">IDXX</a>) shares increased by 10.41% to $466.0. The market value of their outstanding shares is at $38.1 billion. The company's, Q4 earnings came out today. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Viracta Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VIRX#NASDAQ">VIRX</a>) shares decreased by 43.6% to $0.09 during Monday's pre-market session. The company's market cap stands at $3.3 million. </li>
<li>Procaps Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PROC#NASDAQ">PROC</a>) shares declined by 41.11% to $0.94. The company's market cap stands at $105.7 million. </li>
<li>Annovis Bio (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ANVS#NYSE">ANVS</a>) shares decreased by 18.07% to $3.99. The market value of their outstanding shares is at $55.0 million. </li>
<li>Elutia (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ELUT#NASDAQ">ELUT</a>) shares declined by 14.6% to $2.75. The market value of their outstanding shares is at $95.0 million. </li>
<li>Senseonics Holdings (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/SENS#AMEX">SENS</a>) shares fell 12.81% to $0.84. The market value of their outstanding shares is at $498.7 million. </li>
<li>BioCardia (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BCDA#NASDAQ">BCDA</a>) stock declined by 10.94% to $2.2. The company's market cap stands at $10.0 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Movers

ANVS

BCDA

ELUT

GHRS

HCWB

IVVD

PROC

QNCX

RDHL

SENS

VIRX

12 Health Care Stocks Moving In Monday's Pre-Market Session

Press Releases

IDEXX Announces CFO Transition

IDEXX Laboratories Announces Increase in Share Repurchase Program Authorization

SR Inc Announces 2024 SBER Awards: Top Honors Go to Synopsys, Nell Triplett of Juniper Networks, and IDEXX

IDEXX Laboratories to Release 2024 Fourth Quarter and Full Year Financial Results

IDEXX Announces Groundbreaking Cancer Dx Panel with Affordable Early Detection Test for Canine Lymphoma

IDEXX Laboratories Announces Fourth Quarter and Full Year 2024 Results

IDEXX Laboratories to Present at Two Upcoming Institutional Investor Conferences

IDEXX Laboratories to Release 2025 First Quarter Financial Results

IDEXX Laboratories Announces First Quarter Results

IDEXX Laboratories to Present at Stifel Conference and Announces 2025 Investor Day

Comments

IDEXX Laboratories

뉴스

파트너 / 기고자

벤징가 글로벌